Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor PTLD post allogene SCT en PTLD post nier­transplantatie.

Het lokale beleid rondom EBV reactivatie en PTLD post allogene SCT is gebaseerd op de ECIL-6 richtlijn, Styczynski et al., Haematologica 2016.

Literatuur

1. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009 November 5;114(19):4002-8
2. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lympho­proliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008 November;15(6):576-85
3. Annels NE et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simul­taneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006 June 15;42(12):1743-8
4. Parker et al. Diagnosis of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS guidelines. British Journal of Haematology (2010) 149, 675-692
5. Parker et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS guidelines. British Journal of Haematology (2010) 149, 693-705
6. Dierickx et al. How I treat posttransplant lymphoproliferative disorders. Blood (2015) 126, 2274-2283
7. Dierickx et al. Post-transplantation lymphoproliferative disorders in adults (review). NEJM (2018) 378, 549-562
8. Landgren O et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009 May 14; 113(20):4992-5001
9. Cohen JM et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007 February; 48(2):256-69
10. Cohen J et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005 April; 129(2):229-39
11. Styczynski J et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009 May; 43(10):757-70
12. van Esser JW et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002 June 15; 99(12):4364-9
13. van Esser JW et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001 August 15; 98(4):972-8
14. Styczynski J, van der Velden W et al. Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patient after allogeneic hematopoietic stem cell transplantation: Sixth European conference on infections in leukemia (ECIL-6) guidelines. Haematologica. 2016 Jul; 101(7)

Ga terug naar de homepage PTLD post allogene SCT.

Ga terug naar de homepage PTLD post niertransplantatie.

Ga terug naar de homepage EBV reactivatie en PTLD.

Ga terug naar de algemene homepage Behandelprotocollen.